The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study. Children and adolescents 10 years and older with type 2 ...
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52. Half of children and adolescents with moderately to severely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results